2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1428

The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Abstract Number: 1336

The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Abstract Number: 1406

The Scaffold Protein p62 Is Involved In NF-κB Signaling, Caspase-3 Dependent and -Independent Cell Death and Autophagy In Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 734

The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Abstract Number: 512

The Significance Of Ectopic Germinal Center In Minor Salivary Gland Of Patients With Sjögren’s Syndrome
Abstract Number: 2728

The Small Ubiquitin Related Modifier-1 (SUMO-1) Regulates Osteoclast Differentiation In Vitro and In Vivo.
Abstract Number: 1292

The Spatial Energy Expenditure Configuration and Possible Applications In An Experimental Model Of Arthritis
Abstract Number: 1661

The Spectrum of childhood Inflammatory Brain Diseases; An Increasingly Recognised Field
Abstract Number: 2887

The Spondyloarthritis Research Consortium Of Canada MRI Sacroiliac Joint Structural Score: A Method For Reliable Detection Of Structural Progression
Abstract Number: 1951

The Spring Ligament Window: A Unique Sonoanatomic View Into a Complex Rheumatoid Joint
Abstract Number: 1691

The STAT1 Signaling Pathway In Giant Cell Arteritis
Abstract Number: 1086

The Straight Neck in Fibromyalgia
Abstract Number: 1503

The Suppressive Ability Of Altered Peptide Ligands To M3R Reactive T Cells In M3R Induced Autoimmune Sialadenitis
Abstract Number: 546

The Survival Of Gr1⁺CD11b⁺cells Is Differentially Regulated In Male and Female Lupus-Prone Mice
Abstract Number: 120

The Symptom Severity In Korean Patients With Fibromyalgia Is Associated With Socioeconomic Status, But Not With Obesity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].